Navigation Links
Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
Date:10/23/2008

PARIS, October 23 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces positive results from its Phase II clinical trial evaluating NXL103 in the treatment of community acquired pneumonia (CAP). NXL103 is a novel oral streptogramin antibiotic that has potent in vitro activity against certain Gram positive bacteria including methicillin resistant Staphylococcus aureus (MRSA) as well as the important respiratory pathogens including penicillin, macrolide and quinolone resistant strains.

The NXL103 Phase II study was a double-blind, multinational, randomized, comparative study that evaluated this novel oral antibacterial as a treatment for mild to moderate CAP. The study recruited 300 adult patients in 9 countries in both the Northern and Southern hemispheres. Patients were randomised (1:1:1) to three treatment arms: 500mg of NXL103 twice a day, 600mg NXL103 twice a day or 1,000 mg of amoxicillin three times a day for 7 days. The key endpoints of the study were the clinical outcome in the clinically evaluable population at the early follow-up visit (7 to 14 days post-therapy) and safety. In this study, both doses of NXL103 were effective, with clinical response rates similar to those seen in the amoxicillin group. For the primary efficacy analysis, response rates were 91.4% in the 500mg NXL103 group; 94.7% in the 600mg NXL103 group; and 88.5% in the amoxicillin group. NXL103 was generally well tolerated with the most frequent adverse events related to gastrointestinal intolerance. There were no serious drug-related adverse events reported in the study.

The complete results from this Phase II trial will be published in the first half of 2009.

NXL103 has a spectrum of activity that indicates it has the potential to be effective in the treatment of skin and skin structure infections, includi
'/>"/>

SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
2. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
3. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
4. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
5. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
6. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
7. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
8. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
9. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
10. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
11. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... Corporation (Nasdaq: LMNX ) today announced that it ... on Monday, February 3, 2014. A press release announcing the ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the fourth quarter and twelve months ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis ... affordable laser tattoo removal experience with the advanced Astanza Duality laser ... high quality cosmetic services with cutting edge medical technology and offering ... California has seen a dramatic increase in the presence ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... Ultra Clean Holdings, Inc. (Nasdaq: UCTT ), a ... capital equipment, flat panel, medical, energy and research industries will ... October 24, 2011 after markets close. The Company ... results and management,s outlook at 1:45 pm PDT on Monday, ...
... The medical education landscape has changed dramatically ... pressures have reshaped approaches to Continuing Medical Education ... right staffing, investment, and delivery platforms to provide ... To help inform medical education leaders on ...
Cached Medicine Technology:Study Highlights Emerging Approaches to Medical Education in the Pharmaceutical Sector 2
(Date:7/9/2014)... The liver is one of the most important organs ... that we utilize our food properly this is ... removed from our organism this is its detoxification ... and unhealthy food all damage the liver. The resulting ... deposits, cirrhoses, and life-threatening liver failure. According to the ...
(Date:7/9/2014)... studies linking older age with kidney and heart disease ... donation among older adults. However, in the first study ... Perelman School of Medicine at the University of Pennsylvania ... enjoy similar life expectancy and cardiovascular health as very ... In light of the ever increasing organ transplant waitlists, ...
(Date:7/9/2014)... has risen dramatically in Western societies. One frequently cited ... and have fewer infections than previous generations, thereby delaying ... researchers at Sahlgrenska Academy, University of Gothenburg, monitored children ... the immune system in relation to allergic disease. All ... Vstra Gtaland Region, half of them on farms that ...
(Date:7/8/2014)... awarded up to $15 million by the Defense Advanced ... aiming to help brain-injured people restore lost memory functions. ... psychology and physics will collaborate to create, surgically implant, ... Memory is the process in which neurons in certain ... retrieve it. Certain types of illnesses and injuries disrupt ...
(Date:7/8/2014)... found to be three times higher when auditors were ... auditors present, according to a study in a major ... "Quantification of the Hawthorne effect in hand hygiene compliance ... study," published today on-line in the BMJ Quality ... Srigley, who did the study as part of her ...
Breaking Medicine News(10 mins):Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3
... Schools in the ... Country, ... in association with the School Nutrition,Association and the President,s Council on Physical ... as one,of the 25 healthiest schools in the nation. The recognition is ...
... LAKE CITY, Dec. 11 Amedica Corporation, an,orthopedic ... today that the U.S. Food and Drug Administration,has ... Valeo(TM),ceramic VBR spinal implant., The Valeo VBR ... aid in surgical correction and stabilization of the ...
... red meat and processed meat you eat, the higher the ... hamburger or a small pork chop eaten daily could put ... government health researchers report. , The more red meat ... researchers from the National Cancer Institute concluded. , "Red ...
... Panomics Inc., a,developer of innovative technologies ... the exclusive provider of QuantiGene(R) and,QuantiGene Plex(R) ... today that they have been awarded Frost ... Entrepreneurial Company of the Year,Award. Frost & ...
... YORK, Dec. 10 The holiday season is a ... Combine high-calorie,goodies with the cold winter weather, and December ... Fitness Operations VP at 24 Hour Fitness health,clubs, says ... help stave,off extra "holiday" pounds., Listen to this ...
... REDWOOD CITY, Calif., Dec. 10 Cardica, Inc.,(Nasdaq: ... of the over-allotment,option granted to the underwriters of ... their option to purchase,481,170 shares of common stock ... share., William Blair & Company, L.L.C. acted ...
Cached Medicine News:Health News:Local School Wins National got milk?(R) Healthiest Student Bodies Contest 2Health News:Local School Wins National got milk?(R) Healthiest Student Bodies Contest 3Health News:Amedica Receives FDA Special 510(k) Clearance for its Valeo(TM) Ceramic Spinal Implant 2Health News:High Meat Consumption Linked to Heightened Cancer Risk 2Health News:High Meat Consumption Linked to Heightened Cancer Risk 3Health News:High Meat Consumption Linked to Heightened Cancer Risk 4Health News:Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award 2Health News:Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award 3Health News:Cardica Announces Exercise of Over-Allotment Option 2Health News:Cardica Announces Exercise of Over-Allotment Option 3
Detection of antibodies to Malaria in Human whole blood....
Paracheck Pf is a two site sandwich immunoassay for the detection of P. falciparum specific histidine rich protein 2 (Pf HRP-2) in whole blood samples....
This is an antigen-capture assay intended for the detection of histidine-rich protein ll (PfHRP-ll), which is released from Malaria-infected red blood cells....
The Malaria Combo Test is a rapid test for the qualitative detection of Plasmodium falciparum and / or Plasmodium vivax , Plasmodium ovale and Plasmodium malariae antigen in whole blood. This ...
Medicine Products: